Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
LymphomaDisorder Related to Bone Marrow Transplantation
Interventions
DRUG

Fludarabine

25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.

DRUG

Melphalan

70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.

PROCEDURE

Allogeneic Transplant

Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.

DRUG

Thymoglobulin

2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00506129 - Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | Biotech Hunter | Biotech Hunter